CJC-1295 + Ipamorelin: What It Is and How the Combination Is Studied
CJC-1295 + Ipamorelin is a research combination that pairs a GHRH analogue with a selective growth hormone secretagogue. Laboratories use the pair when they want to examine two complementary growth hormone–related signaling routes within one experimental framework.
CJC-1295 without DAC is studied as a growth hormone–releasing hormone (GHRH) analogue. Ipamorelin is studied for selective ghrelin-receptor (GHS-R) activity. Together, they appear in research discussions about coordinated growth hormone axis signaling. The combination is supplied for laboratory use only and is not approved as a medicine in Canada or the United States.
What Each Compound Is
CJC-1295 (no DAC) A synthetic GHRH analogue designed for research on growth hormone–releasing hormone pathways. The “no DAC” form lacks the Drug Affinity Complex modification. As a result, it is discussed as a shorter-acting research tool compared with DAC-linked analogues. Clear identification of the no-DAC version matters because the two forms are not interchangeable in experimental design.
Ipamorelin A selective growth hormone secretagogue studied for activity at the ghrelin receptor. In research literature, it is often noted for a cleaner selectivity profile relative to older secretagogues that interacted with a broader set of pathways.
Used together, the pair allows researchers to examine GHRH-pathway activity and ghrelin-receptor activity in related experimental designs rather than in isolation.
Why Researchers Combine CJC-1295 + Ipamorelin

The logic is complementary signaling, not identical action.
| Compound | Primary research angle |
|---|---|
| CJC-1295 no DAC | GHRH-pathway signaling |
| Ipamorelin | Ghrelin-receptor / GHS signaling |
| Combination | Dual-route growth hormone axis research models |
CJC-1295 Ipamorelin discussions usually focus on whether studying both routes together is more useful than studying either route alone. That is a design question. It depends on the protocol, endpoints, timing, and controls.
Useful background papers include:
- Teichman et al. (2006) – examined prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GHRH analogue
- Raun et al. (1998) – characterized Ipamorelin as the first selective growth hormone secretagogue, with a cleaner selectivity profile relative to older GHRP compounds
These papers help map each compound’s individual research background. They do not create an approved clinical combination product out of research materials.
CJC-1295 No DAC vs Other Versions
Naming precision is essential here.
- CJC-1295 no DAC usually refers to the analogue without the Drug Affinity Complex
- CJC-1295 with DAC refers to a longer-acting modified version discussed differently in the literature
If a protocol or product listing says “CJC-1295 Ipamorelin,” confirm whether the CJC component is the no-DAC form. Identity should come from documentation and sequence data, not from informal shorthand. Using the wrong version introduces a variable that can undermine comparison across studies.
What Combination Research Is Actually Testing
A dual-compound design can ask several distinct questions:
- What happens when GHRH-pathway activity and ghrelin-receptor activity are examined in the same model?
- Do measured endpoints differ from single-compound runs under matched conditions?
- Are preparation, timing, and handling variables stable enough for clean comparison?
Those are experimental questions. They require clear material identity, controlled preparation, and matched documentation for both peptides. A blend is only as interpretable as the characterization of each component.
Bodybuilding and Performance Research Discussions
CJC-1295 + Ipamorelin frequently appears in bodybuilding and performance-oriented research conversations because both compounds are associated with growth hormone axis signaling. In those discussions, the pairing is often framed as a way to examine complementary routes that influence GH-related pathways rather than relying on a single mechanism.
It is important to separate community interest from laboratory reality. Most formal published work examines the compounds individually or in controlled preclinical models. Informal “stack” language does not replace sequence identity, purity data, or experimental controls. When researchers evaluate this combination for growth hormone axis studies, the value comes from clear documentation and consistent handling—not from popular naming conventions used outside the lab.
Any material offered under this pairing remains intended strictly for research and laboratory use. It is not a therapeutic product, training aid, or approved performance compound.
Material Quality for the Pair
For CJC-1295 Ipamorelin work, evaluate both compounds:
- Batch-specific Certificates of Analysis
- HPLC purity data
- Identity confirmation for each peptide
- Consistent labeling and lot tracking
If the product is a pre-combined research blend, the paperwork should still make both components clear. If the compounds are supplied as separate vials, keep independent lot records for each one. This is especially important for combination research. When one material is well documented and the other is not, the entire comparison weakens.
Handling Notes
Reconstitute lyophilized material with sterile diluent under controlled conditions. Pharmaceutical-grade bacteriostatic water is commonly preferred for multi-draw laboratory workflows.
Store dry material cold and protected from light. Keep preparation conditions consistent across the study window. If cloudiness appears after reconstitution, check diluent quality before assuming the peptide itself failed.
For dual-compound protocols, consistency between the two preparations matters. Uneven handling can create differences that look like pathway effects when they are actually preparation artifacts.
Where This Combination Fits
The CJC-1295 Ipamorelin pair is most relevant when the research question involves growth hormone axis signaling and the team specifically wants both GHRH-related and ghrelin-receptor-related tools available in the same experimental framework.
It is less relevant when a study only needs one route. In that case, a single-compound design is cleaner and easier to interpret.
A practical decision framework:
- One pathway question → one compound
- Dual-route question → combination design with clear controls
- Loose interest in “GH peptides” → refine the research question before selecting materials
Practical Takeaways
- CJC-1295 + Ipamorelin pairs a GHRH analogue with a selective growth hormone secretagogue.
- CJC-1295 no DAC should be identified clearly in documentation and distinguished from DAC versions.
- Ipamorelin peptide research centers on ghrelin-receptor selectivity.
- Combination work requires COAs and identity data for both components.
- Protocol design should follow pathway questions, not informal stack names alone.
Summary of CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin is a research pairing used to examine complementary growth hormone–related signaling routes. CJC-1295 no DAC is studied as a GHRH analogue. Ipamorelin is studied as a selective growth hormone secretagogue. Together, they appear in dual-route experimental designs where material identity, purity documentation, and controlled handling determine how readable the results are.

Looking for research-grade CJC-1295 no DAC + Ipamorelin material? → 5mg + 5mg vial
For research and laboratory use only. Not for human or animal consumption. This material has not been evaluated by Health Canada or the FDA and is not intended to diagnose, treat, cure, or prevent any disease or condition.
Looking for more peptide research?








